December 2025 in “JEADV Clinical Practice” These new skin treatments are safer and more effective with minimal side effects.
October 2021 in “Journal of Investigative Dermatology” Blocking IL-12 can help treat alopecia areata by preventing hair follicle immune issues.
7 citations
,
November 2023 in “JAAD Case Reports” Baricitinib helped regrow hair in patients with severe alopecia areata after other treatments failed.
February 2025 in “International Journal of STD & AIDS” Tofacitinib can cause unusual hair growth, requiring careful monitoring and possible laser hair removal.
October 2014 in “Cancer Research” A new topical treatment may prevent hair loss from cancer therapy by adjusting cell death processes in hair follicles.
22 citations
,
June 2002 in “Journal of Medicinal Chemistry” Compounds 15, 20, and 25 are strong inhibitors of human steroid 5α-reductase type 2.
Flutamide helps with prostate cancer and some skin conditions but can harm the liver.
July 2025 in “Journal of Investigative Dermatology” Upadacitinib effectively treats pyoderma gangrenosum.
29 citations
,
December 2019 in “Expert review of clinical pharmacology” JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.
55 citations
,
October 2019 in “Dermatology and therapy” Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.
9 citations
,
January 2015 in “Medical hypotheses” TCDD disrupts skin stem cells, causing skin issues like chloracne.
Diane and Androcur 10 improved acne and seborrhea in most women, and hirsutism and alopecia in about half.
February 2020 in “Oncology Times” Antibody drug conjugates show promise in targeting cancer cells while reducing harm to healthy cells.
2 citations
,
January 2023 in “Prague Medical Report” JAK inhibitors, like baricitinib, are effective and safe for treating alopecia areata.
4 citations
,
May 2019 in “Sultan Qaboos University Medical Journal” Tofacitinib helped regrow hair in a patient with severe hair loss and improved their quality of life without side effects.
2 citations
,
January 2020 in “Evidence-based Complementary and Alternative Medicine” Hataedock treatment improved skin health and reduced atopic dermatitis symptoms by enhancing the skin barrier and reducing inflammation.
Hit15 shows promise as a COVID-19 treatment by reducing virus infection and inflammation.
3 citations
,
January 1990 in “Cancer chemotherapy and pharmacology” Topical thiols may prevent hair loss caused by certain chemotherapy drugs.
32 citations
,
March 2009 in “AAPS PharmSciTech” 9 citations
,
January 2009 in “Journal of the European Academy of Dermatology and Venereology” The cream effectively reduces excessive hair growth and related skin issues without side effects.
March 2026 in “The American Journal of Managed Care” JAK inhibitors can help treat alopecia areata but have risks and high costs.
April 2023 in “Journal of Investigative Dermatology” ALRN-6924 can protect hair follicles from chemotherapy damage by temporarily stopping cell division.
2 citations
,
January 2012 in “Hair therapy & transplantation” DDAIP-HCl significantly increases minoxidil absorption into the skin.
139 citations
,
November 2016 in “Journal of the American Academy of Dermatology” Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.
3 citations
,
April 2021 in “Oncology Times” Trodelvy™ helped some patients with advanced breast cancer, but had side effects.
October 2023 in “Applied materials today” New treatment for hair loss using special microneedles shows promise in reducing inflammation and promoting hair growth.
January 2025 in “Journal of Cutaneous Immunology and Allergy” Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.
61 citations
,
April 2014 in “Radiation Research” RTA 408 cream protects mice from radiation skin damage.
36 citations
,
June 2014 in “Experimental Neurology” Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.
6 citations
,
October 2024 in “Journal of Family Medicine and Primary Care” Primary care doctors need to monitor JAK and TYK-2 inhibitors carefully for skin conditions.